Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
<h4>Background</h4>Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC...
Guardado en:
Autores principales: | Esther Conde, Ana Suárez-Gauthier, Amparo Benito, Pilar Garrido, Rosario García-Campelo, Michele Biscuola, Luis Paz-Ares, David Hardisson, Javier de Castro, M Carmen Camacho, Delvys Rodriguez-Abreu, Ihab Abdulkader, Josep Ramirez, Noemí Reguart, Marta Salido, Lara Pijuán, Edurne Arriola, Julián Sanz, Victoria Folgueras, Noemí Villanueva, Javier Gómez-Román, Manuel Hidalgo, Fernando López-Ríos |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a2ee3e16eccc4c4487381ac1367b8191 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.
por: Pablo Martinez, et al.
Publicado: (2013) -
FDA consumer
Publicado: (1972) -
FDA-MIMO Beampattern Synthesis with an Analytical Method
por: Changlin Zhou, et al.
Publicado: (2021) -
Robustness in an Ultrasensitive Motor
por: Guangzhe Liu, et al.
Publicado: (2020) -
Rationale for Use of an FDA-Cleared Delivery System for Administration of Inhaled Nitric Oxide in Patients Undergoing Magnetic Resonance Imaging
por: Salas M, et al.
Publicado: (2021)